(Reuters) -Indian drugmaker Divi’s Laboratories reported second-quarter profit above analysts’ estimates on Friday, helped by its business that focuses on customised production of chemical compounds used in drugs.

Consolidated net profit rose to 6.89 billion rupees ($78.39 million) in the quarter ended September 30 from 5.10 billion rupees a year earlier, the Hyderabad-based company said.

That was above analysts’ average estimate of 5.87 billion rupees, according to data compiled by LSEG.

Revenue from operations rose 16% to 21.15 billion rupees, compared with analysts’ estimates of 24.86 billion rupees.

Indian generic drugmakers, which earn a significant chunk of their revenue from the United States, have been struggling with weak pricing in the world’s top economy amid stiff competiti

See Full Page